Abstract

The HAS recommends integrating the VidPrevtyn Beta vaccine in subjects over 18 years old vaccinated with an mRNA or adenoviral vector vaccine against Covid-19 as an alternative to bivalent mRNA vaccines for people reluctant to this type of vaccine and those who cannot benefit from it (contraindications). HAS recalls that, in accordance with the current booster vaccination strategy, an additional dose should preferably be given with a bivalent mRNA vaccine (Spikevax bivalent Original/Omicron BA.1, Comirnaty bivalent Original/Omicron BA.1, Comirnaty bivalent Original/ Omicron BA.4-5, Spikevax bivalent Original/Omicron BA.4-5), regardless of the vaccine(s) previously used.

  • Recommendation
  • Europe
  • France
  • booster dose
  • COVID-19